Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF

ABSTRACT Aim Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all‐cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney dysfunction due to better oral bioa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of heart failure 2024-05, Vol.26 (5), p.1242-1250
Hauptverfasser: Martens, Pieter, Greene, Stephen J., Mentz, Robert J., Li, Shuang, Wojdyla, Daniel, Kapelios, Chris J., Mullens, Wilfried, Hall, Michael E., Ketema, Fassil, Kim, Dong‐Yun, Eisenstein, Eric L., Anstrom, Kevin, Fang, James C., Pitt, Bertram, Velazquez, Eric J., Tang, W.H. Wilson
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Aim Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all‐cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney dysfunction due to better oral bioavailability and longer half‐life, but direct supportive evidence is lacking. Methods and results The TRANSFORM‐HF trial randomized patients hospitalized for HF to a long‐term strategy of torsemide versus furosemide, and enrolled patients across the spectrum of renal function (without dialysis). In this post‐hoc analysis, baseline renal function during the index hospitalization was assessed as categories of estimated glomerular filtration rate (eGFR;
ISSN:1388-9842
1879-0844
1879-0844
DOI:10.1002/ejhf.3207